Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful faithfully but unsuccessfully to create an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past few shares. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good In order to Be True?”, set away what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire employment interview which I came away with a poor opinion of the business.

Irony of irony, the poor opinion of mine of the business has grown steadily, however, the disappointment has not been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger at the moment still disappoints? Therein is the story; permit me to explain.

CytoDyn acquired its much-storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor of the therapy as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this know-how and linked intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 million) as well as the very first new drug application endorsement ($5 million), and even royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market place cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with numerous therapies and many indications, it’s this single treatment in addition to a “broad pipeline of indications” as it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an active business with diverse interests albeit centered on leronlimab, multiple disease sorts, multiple publications in addition to multiple delivering presentations.

Can it all be smoke cigarettes and mirrors? That is a question I have been asking myself with the very beginning of my interest in this particular business. Judging with the multiples of thousands of diverse commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *